Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
VA Study Calls for Tighter Regulation of Data Center Water Use Virginia, a leading data center market , released a long-delayed report examining the industry’s possible impact on the groundwater...
‘No Robo Bosses Act’ on Move in CA A fast-moving bill in California ( SB 947 ) would require human oversight when employers use artificial intelligence in certain employment decisions. Introduced...
Last year, Colorado became the first state to use a prescription drug affordability board to set a binding payment limit for a specific drug. Now a federal judge has temporarily blocked that limit, raising...
FDA Advisory Panel Supports Widening Access to Several Peptides Last week an advisory committee to the Food and Drug Administration voted in favor of allowing compounding pharmacies to produce six peptides...
OH EPA Scraps Proposed Data Center Water Discharge General Permit The Ohio Environmental Protection Agency announced in a community notice last week that after “carefully reviewing the significant...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
Virginia lawmakers have passed legislation (SB 271/HB 483) that would create a prescription drug affordability board to review drug prices and set limits on how much state-regulated health plans can pay for drugs. The legislation is similar to that enacted in other states, but Virginia’s would be the first linking the board’s activity to drug price negotiations between manufacturers and Medicare mandated by the federal Inflation Reduction Act of 2022. (PLURIBUS NEWS, LEXISNEXIS STATE NET)
After decades of debating whether to restrict direct-to-consumer drug advertising, the Trump administration and federal lawmakers appear to be moving in that direction.
Last February, U.S. Sen. Angus King (I-ME) introduced a bill (SB 483) prohibiting drugs from being advertised directly to consumers for three years after they receive FDA approval. The measure is still pending.
In September President Trump issued a presidential memorandum calling for the reversal of a 1997 policy change that allowed drug advertising on television. On the same day, the FDA announced that it was “sending thousands of letters warning pharmaceutical companies to remove misleading ads and issuing approximately 100 cease-and-desist letters to companies with deceptive ads.” (NEW YORK TIMES)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.